Innate Pharma SA (IPHA) Q2 2026 Earnings Call

Concluded Aug 14, 2026

Aug 14, 2026 0 turns

Period: FY2026 Q2
Runtime: —
Sources: 1 artifact

6-K

Executive readout · one minute

Call research workspace

Read the call alongside every captured source. 6-K call announcement stays in one workspace.

IPH4502 Nectin-4 ADC 22 Monalizumab / Pacific 9 14 ADC preclinical portfolio 11 Sobi strategic partnership (lacutamab) 11 Competitive landscape in Nectin-4 ADCs 6 Equity raise and cash runway 5

Management tone

Confident

Net tone +50 · moderate hedging

Grounding quotes

“This week has been a very busy and important week for innate pharma, putting in place the critical elements which allow continued advancement of the strategic agenda which we announced in September last year.”
“I think we're feeling quite confident that we have a window here from a dosing perspective where IPH4502 will be effective.”
“we have an exciting portfolio of preclinical ADCs, which we will reveal in due course at the appropriate time”
“The $30 million raised, together with the $75 million upfront payment payable upon closing of the strategic partnership with Sobe, extends our projected cash runway through Q1 2028.”

Research coverage

1 live source

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

6-K call announcement Filed Aug 14, 2026 Company webcastOpen the original investor-relations page

Read transcripts like this one from Claude, ChatGPT or your own code with the earnings call transcript API →